SNPMiner Trials (Home Page)
Report for Clinical Trial NCT02857270
Developed by Shray Alag, 2020.
SNP Clinical Trial Gene
The purpose of this study is to determine the safety of an extracellular signal regulated
kinase (ERK1/2) inhibitor LY3214996 administered alone or in combination with other agents in
participants with advanced cancer.
Name: LY3214996
Description: Administered orally
Type: Drug
Group Labels: 8 Japan Part 1 Japan Part 2 LY3214996 + Abemaciclib LY3214996 + Encorafenib + Cetuximab LY3214996 + Midazolam LY3214996 + Nab-Paclitaxel + Gemcitabine LY3214996 Dose Escalation LY3214996 Dose Expansion
Name: Midazolam
Description: Administered orally
Type: Drug
Group Labels: 1 LY3214996 + Midazolam
Name: Abemaciclib
Description: Administered orally
Type: Drug
Group Labels: 2 Japan Part 2 LY3214996 + Abemaciclib
Name: Nab-paclitaxel
Description: Administered IV
Type: Drug
Group Labels: 1 LY3214996 + Nab-Paclitaxel + Gemcitabine
Name: Gemcitabine
Description: Administered IV
Type: Drug
Group Labels: 1 LY3214996 + Nab-Paclitaxel + Gemcitabine
Name: Encorafenib
Description: Administered orally
Type: Drug
Group Labels: 1 LY3214996 + Encorafenib + Cetuximab
Name: Cetuximab
Description: Administered IV
Type: Drug
Group Labels: 1 LY3214996 + Encorafenib + Cetuximab
Primary Outcomes
Measure: Number of Participants with LY3214996 Dose Limiting Toxicities (DLTs) Time: Cycle 1 (21 Days)
Secondary Outcomes
Measure: Pharmacokinetics (PK): Area Under the Concentration-Time Curve (AUC) of LY3214996 Administered as Monotherapy and when Administered in Combination with Nab-Paclitaxel Plus Gemcitabine, Abemaciclib and Encorafenib Plus Cetuximab Time: Cycle 1 Day 1 through Cycle 2 Day 1 (up to 28 Day Cycles)
Measure: PK: AUC of Gemcitabine when Administered with LY3214996 Time: Cycle 1 Day 1 through Cycle 1 Day 15 (28 Day Cycles)
Measure: PK: AUC of Nab-Paclitaxel when Administered with LY3214996 Time: Cycle 1 Day 1 through Cycle 1 Day 15 (28 Day Cycles)
Measure: PK: AUC of Abemaciclib and its Metabolites when Administered with LY3214996 Time: Cycle 1 Day 1 through Cycle 2 Day 1 (up to 22 Day Cycles)
Measure: PK: AUC of Encorafenib when Administered with LY3214996 Time: Cycle 1 Day 1 through Cycle 2 Day 1 (up to 22 Day Cycles)
Measure: PK: AUC of Cetuximab when Administered with LY3214996 Time: Cycle 1 Day 1 through Cycle 2 Day 1 (up to 22 Day Cycles)
Measure: PK: AUC of Midazolam and its 1'-Hydroxymidazolam Metabolite when Administered Alone and in Combination with LY3214996 Time: Cycle 1 Day 1 through Cycle 1 Day 16 (21 Day Cycles)
Measure: Objective Response Rate (ORR): Percentage of Participants With a Complete (CR) or Partial Response (PR) Time: Baseline to Measured Progressive Disease or Start of New Anti-Cancer Therapy (Estimated up to 6 Months)
Measure: Duration of Response (DoR) Time: Date of Complete Response (CR) or Partial Response (PR) to Date of Objective Disease Progression or Death Due to Any Cause (Estimated up to 12 Months)
Measure: Time to First Response (TTR) Time: Baseline to Date of CR or PR (Estimated up to 6 Months)
Measure: Progression Free Survival (PFS) Time: Baseline to Progressive Disease or Death of Any Cause (Estimated up to 12 Months)
Measure: Disease Control Rate (DCR): Percentage of Participants who Exhibit Stable Disease (SD), CR or PR Time: Baseline through Measured Progressive Disease (Estimated up to 6 Months)
Measure: Overall Survival (OS) (Dose Expansion Arms Only) Time: Baseline to Date of Death from Any Cause (Estimated up to 2 Years)
Purpose: Treatment
Allocation: Non-Randomized
Parallel Assignment
There is one SNP
SNPs
1 V600E
- Part E: Metastatic BRAF V600E colorectal cancer. --- V600E ---